Working toward delivering a significant
improvement in the health and quality of life
to future generations living with XLHED
Edimer Pharmaceuticals
Edimer Pharmaceuticals is dedicated to developing EDI200 as a treatment for X-linked Hypohidrodic Ectodermal Dysplasia (XLHED). XLHED is a rare, orphan disease that causes a range of symptoms including lack of sweat glands, poor temperature control, respiratory problems, and hair and tooth malformations.
Edimer is led by a team of seasoned biotechnology industry veterans with deep experience in drug development complemented by a strong network of world-class clinical and scientific advisors. The company is based in Cambridge, Massachusetts.